We rank companies based on fund manager, research analyst and news sentiment
AVTE stock icon

Aerovate Therapeutics
AVTE

$24.73
2.02%
 

About: Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

Employees: 51

0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

66% more capital invested

Capital invested by funds: $386M [Q3] → $640M (+$253M) [Q4]

38% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 16

9% more funds holding

Funds holding: 58 [Q3] → 63 (+5) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]

0.81% less ownership

Funds ownership: 102.95% [Q3] → 102.14% (-0.81%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$35
42%
upside
Avg. target
$50
102%
upside
High target
$65
163%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Wells Fargo
Tiago Fauth
42%upside
$35
Overweight
Maintained
1 Apr 2024
Jefferies
Eun Yang
163%upside
$65
Buy
Assumed
25 Mar 2024

Financial journalist opinion